

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

STATUS OF WAIVER ON THE SPECIFIC PERFORMANCE COVENANT UNDER LOAN AGREEMENT

This announcement is made by Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.19 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“Listing Rules”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 17 October 2012 and 6 June 2014 (the “**Announcements**”) which, among other things, disclosed that a loan agreement for a 3 years term loan facility of US\$16,500,000 which was entered into between New Orient as borrower and Hang Seng Bank as lender on 17 October 2012, which contains specific performance obligations imposed on the controlling shareholders of the Company. Mr. Wu Qin has resigned as an executive Director and chairman of the Board of the Company with effect from 4 June 2014 that made New Orient failed to compile with one of the specific performance obligations, and therefore has constituted an event of default under the loan agreement. Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements unless otherwise stated.

New Orient obtained a waiver today from Hang Seng Bank for waiving of the non-compliance on specific performance obligation. As of the announcement date, after obtaining the waiver, there is no any non-compliance or event of default on any terms of the loan agreement of the Group.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the securities of the Company.

By Order of the Board
Chan Ka Kit
Company Secretary

Hong Kong, 11 June 2014

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.